Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence
Nat Biomed Eng. 2025;:ePub - PMID: 41125869 - DOI: 10.1038/s41551-025-01533-2
Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity.
Immunity. 2025;:ePub - PMID: 41421339 - DOI: 10.1016/j.immuni.2025.11.020
A Myeloid Cell-Targeted Immunostimulant Cocktail (MyTai) Enhances Cancer Immunotherapy.
ACS Nano. 2025;19(41):36451-36464 - PMID: 41061756 - DOI: 10.1021/acsnano.5c10081
Recent developments in myeloid immune modulation in cancer therapy.
Trends Cancer. 2025;11(4):365-375 - PMID: 39794212 - DOI: 10.1016/j.trecan.2024.12.003
Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge.
Targeting myeloid cell polarization to prevent GBM recurrence.
Mol Ther. 2025;:ePub - PMID: 41421347 - DOI: 10.1016/j.ymthe.2025.12.019
Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer
Cell Rep Med. 2025;6(5):102100 - PMID: 40311615 - PMCID: PMC12147904 - DOI: 10.1016/j.xcrm.2025.102100
7
CSV